Literature DB >> 20060929

Negative feedback loop of BRCA1-BARD1 ubiquitin ligase on estrogen receptor alpha stability and activity antagonized by cancer-associated isoform of BARD1.

Eva Dizin1, Irmgard Irminger-Finger.   

Abstract

Estrogen is involved in breast cancer risk, which is increased for BRCA1 mutation carriers, suggesting a role for BRCA1 in estrogen signaling. BRCA1 exerts its function through forming an E3 ubiquitin ligase with BARD1. We report that the estrogen receptor alpha is a target of the BRCA1-BARD1 ubiquitin ligase in vivo. BRCA1 and BARD1 are required for estrogen receptor alpha ubiquitination and degradation, and repression of either one leads to ERalpha accumulation, suggesting a feedback loop between BRCA1-BARD1 and estrogen receptor alpha, since BRCA1 and BARD1 are induced by estrogen receptor alpha. While the ubiquitin ligase activity maps to the N-terminal RING finger domains of BRCA1 and BARD1, we demonstrate that the BARD1 C-terminus is important for target recognition. Furthermore, a BARD1 isoform lacking the RING domain binds and stabilizes estrogen receptor alpha. Thus deficiencies of BRCA1 or BARD1 and/or upregulation of BARD1 isoforms lead to estrogen receptor alpha upregulation, providing a functional link between BRCA1 deficiency, estrogen signaling, and tumorigenesis. 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20060929     DOI: 10.1016/j.biocel.2009.12.025

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  19 in total

Review 1.  Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy.

Authors:  Wen Zhou; Joyce M Slingerland
Journal:  Nat Rev Cancer       Date:  2014-01       Impact factor: 60.716

Review 2.  Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.

Authors:  Marieke A Vollebergh; Jos Jonkers; Sabine C Linn
Journal:  Cell Mol Life Sci       Date:  2011-09-16       Impact factor: 9.261

Review 3.  Ubiquitylation of nuclear receptors: new linkages and therapeutic implications.

Authors:  Kyle T Helzer; Christopher Hooper; Shigeki Miyamoto; Elaine T Alarid
Journal:  J Mol Endocrinol       Date:  2015-05-05       Impact factor: 5.098

4.  Substitution of aspartic acid with glutamic acid at position 67 of the BRCA1 RING domain retains ubiquitin ligase activity and zinc(II) binding with a reduced transition temperature.

Authors:  Apichart Atipairin; Bhutorn Canyuk; Adisorn Ratanaphan
Journal:  J Biol Inorg Chem       Date:  2010-10-22       Impact factor: 3.358

Review 5.  A guide for functional analysis of BRCA1 variants of uncertain significance.

Authors:  Gaël A Millot; Marcelo A Carvalho; Sandrine M Caputo; Maaike P G Vreeswijk; Melissa A Brown; Michelle Webb; Etienne Rouleau; Susan L Neuhausen; Thomas v O Hansen; Alvaro Galli; Rita D Brandão; Marinus J Blok; Aneliya Velkova; Fergus J Couch; Alvaro N A Monteiro
Journal:  Hum Mutat       Date:  2012-07-16       Impact factor: 4.878

6.  Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity.

Authors:  Kristopher R Bosse; Sharon J Diskin; Kristina A Cole; Andrew C Wood; Robert W Schnepp; Geoffrey Norris; Le B Nguyen; Jayanti Jagannathan; Michael Laquaglia; Cynthia Winter; Maura Diamond; Cuiping Hou; Edward F Attiyeh; Yael P Mosse; Vanessa Pineros; Eva Dizin; Yongqiang Zhang; Shahab Asgharzadeh; Robert C Seeger; Mario Capasso; Bruce R Pawel; Marcella Devoto; Hakon Hakonarson; Eric F Rappaport; Irmgard Irminger-Finger; John M Maris
Journal:  Cancer Res       Date:  2012-02-20       Impact factor: 12.701

7.  XAF1 destabilizes estrogen receptor α through the assembly of a BRCA1-mediated destruction complex and promotes estrogen-induced apoptosis.

Authors:  Ji-Sun Lim; Kyung-Woo Lee; Kyung-Phil Ko; Seong-In Jeong; Byung-Kyu Ryu; Min-Goo Lee; Sung-Gil Chi
Journal:  Oncogene       Date:  2022-04-16       Impact factor: 9.867

8.  ERα phosphorylation at Y537 by Src triggers E6-AP-ERα binding, ERα ubiquitylation, promoter occupancy, and target gene expression.

Authors:  Jun Sun; Wen Zhou; Kosalai Kaliappan; Zafar Nawaz; Joyce M Slingerland
Journal:  Mol Endocrinol       Date:  2012-08-03

9.  USP35, regulated by estrogen and AKT, promotes breast tumorigenesis by stabilizing and enhancing transcriptional activity of estrogen receptor α.

Authors:  Jiawei Cao; Du Wu; Guang Wu; Yaqi Wang; Tianhao Ren; Yang Wang; Yingshuai Lv; Wei Sun; Jieyi Wang; Changrui Qian; Licai He; Kaiyan Yang; Hongzhi Li; Haihua Gu
Journal:  Cell Death Dis       Date:  2021-06-15       Impact factor: 8.469

10.  Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2.

Authors:  Tomas Kirchhoff; Mia M Gaudet; Antonis C Antoniou; Lesley McGuffog; Manjeet K Humphreys; Alison M Dunning; Stig E Bojesen; Børge G Nordestgaard; Henrik Flyger; Daehee Kang; Keun-Young Yoo; Dong-Young Noh; Sei-Hyun Ahn; Thilo Dork; Peter Schürmann; Johann H Karstens; Peter Hillemanns; Fergus J Couch; Janet Olson; Celine Vachon; Xianshu Wang; Angela Cox; Ian Brock; Graeme Elliott; Malcolm W R Reed; Barbara Burwinkel; Alfons Meindl; Hiltrud Brauch; Ute Hamann; Yon-Dschun Ko; Annegien Broeks; Marjanka K Schmidt; Laura J Van 't Veer; Linde M Braaf; Nichola Johnson; Olivia Fletcher; Lorna Gibson; Julian Peto; Clare Turnbull; Sheila Seal; Anthony Renwick; Nazneen Rahman; Pei-Ei Wu; Jyh-Cherng Yu; Chia-Ni Hsiung; Chen-Yang Shen; Melissa C Southey; John L Hopper; Fleur Hammet; Thijs Van Dorpe; Anne-Sophie Dieudonne; Sigrid Hatse; Diether Lambrechts; Irene L Andrulis; Natalia Bogdanova; Natalia Antonenkova; Juri I Rogov; Daria Prokofieva; Marina Bermisheva; Elza Khusnutdinova; Christi J van Asperen; Robert A E M Tollenaar; Maartje J Hooning; Peter Devilee; Sara Margolin; Annika Lindblom; Roger L Milne; José Ignacio Arias; M Pilar Zamora; Javier Benítez; Gianluca Severi; Laura Baglietto; Graham G Giles; Amanda B Spurdle; Jonathan Beesley; Xiaoqing Chen; Helene Holland; Sue Healey; Shan Wang-Gohrke; Jenny Chang-Claude; Arto Mannermaa; Veli-Matti Kosma; Jaana Kauppinen; Vesa Kataja; Bjarni A Agnarsson; Maria A Caligo; Andrew K Godwin; Heli Nevanlinna; Tuomas Heikkinen; Zachary Fredericksen; Noralane Lindor; Katherine L Nathanson; Susan M Domchek; Niklas Loman; Per Karlsson; Marie Stenmark Askmalm; Beatrice Melin; Anna von Wachenfeldt; Frans B L Hogervorst; Martijn Verheus; Matti A Rookus; Caroline Seynaeve; Rogier A Oldenburg; Marjolijn J Ligtenberg; Margreet G E M Ausems; Cora M Aalfs; Hans J P Gille; Juul T Wijnen; Encarna B Gómez García; Susan Peock; Margaret Cook; Clare T Oliver; Debra Frost; Craig Luccarini; Gabriella Pichert; Rosemarie Davidson; Carol Chu; Diana Eccles; Kai-Ren Ong; Jackie Cook; Fiona Douglas; Shirley Hodgson; D Gareth Evans; Rosalind Eeles; Bert Gold; Paul D P Pharoah; Kenneth Offit; Georgia Chenevix-Trench; Douglas F Easton
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.